Schizophrenia Spectrum and Other Psychotic Disorders
Marked disorders of thought (delusions, hallucinations, or other thought disorder accompanied by disordered affect or behavior), and deterioration from a previous level of functioning. Individuals have one o more of the following symptoms: delusions, hallucinations, and disorganized speech. (from DSM-5)
Subtype terms (7)
More specific conditions that are subtypes of Schizophrenia Spectrum and Other Psychotic Disorders in the MeSH hierarchy.
- Affective Disorders, Psychotic
13 drugs (10 approved, 3 experimental)
- Capgras Syndrome
- Delusional Parasitosis
- Morgellons Disease
- Paranoid Disorders
1 drug approved
- Psychotic Disorders
203 drugs (142 approved, 61 experimental)
- Schizophrenia
474 drugs (241 approved, 233 experimental)
Drugs by status
Phase 4 trials (19)
Phase 3 trials (1)
Phase 2 trials (6)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (17)
- National Institute on Drug Abuse (NIDA)
- Brown University
- University of London
- Federal Neuro-Psychiatric Hospital, Yaba
- NHS Fife
- NHS Lothian
- University of Edinburgh
- University of Manchester
- University of Birmingham
- University of Cambridge
- Salford Royal Foundation NHS Trust
- Lancashire Teaching Hospitals NHS Foundation Trust
- South London and Maudsley NHS Foundation Trust
- West London Mental Health NHS Trust
- North East London Foundation Trust
- Camden and Islington NHS Foundation Trust
- NHS Borders
Organization Involved with Phase 1 Indications (1)